Meningitis vaccine is expected to reach a value of USD 6.32 billion by 2024 at CAGR of 11.8%

June, 2018 | Source: Profshare Market Research

Meningitis vaccine Market expected to reach a value of USD 6.32 billion by 2024 at CAGR of 11.8%.  


Expanding at a CAGR of 11.8% during the period 2018–2024, the market for Meningitis vaccines is expected to reach a value of USD 6.32 billion by 2024. Meningitis disease can become life threatening quickly, and teens are at higher risk of getting it. It's a leading cause of bacterial meningitis in teens.  


Meningitis is a dangerous inflammation of the lining of the brain and spinal cord. Two meningitis vaccines protects against four types of Meningitis disease. An additional type of vaccine protects against serotype B, which also causes meningitis.Of the 1,000-2,600 people who get Meningitis disease each year, one-third are teens and young adults. Ten percent to 15% of those who get sick with the disease will die, even with antibiotic treatment. As many as 20% will have permanent side effects, such as hearing loss or brain damage.The immunization can help prevent this serious disease.  


Meningitis vaccine market

There are six different variant of vaccines available in the United States to protect against Neisseria meningitidis bacteria. Which vaccine a person should get depends on their age and other factors. Some people should get one vaccine to protect against Meningitis vaccine types A, C, W, Y, and a second vaccine to protect against Meningitis vaccine type B.  


There are three vaccines to protect against Neisseria meningitidis bacteria types A, C, W, and Y:Menomune The Food and Drug Administration (FDA) approved this vaccine in 1981. It is approved for use in people 2 years of age and older. It is the only Meningitis vaccine vaccine licensed for people older than 55 years of age.Menactra FDA approved this vaccine in 2005. It is approved for use in people aged 9 months through 55 years of age.  


Menveo FDA approved this vaccine in 2010. It is approved for use in people aged 2 months through 55 years of age.There is one vaccine to protect against Neisseria meningitidis bacteria types C and Y intended specifically for infants and toddlers:MenHibrix FDA approved this vaccine in 2012. It provides protection against two Meningitis vaccine serogroups along with Haemophilus influenzae type b (Hib). It is approved for use in children aged 6 weeks through 18 months of age.There are two vaccines to protect against Neisseria meningitidis bacteria type Trumenba FDA approved this vaccine in 2018 for use in people 10 through 25 years of age.Bexsero FDA approved this vaccine in 2015 for use in people 10 through 25 years of age.  



Geographically, the Meningitis vaccine market is segmented into Asia Pacific, North America, Europe, and Rest of the World (RoW). Of these, currently North America dominates the market and held the major revenue share in 2013. The substantial increase in growth rate of this regional market is driven by a number of public awareness campaigns and infants’ immunization programs by governments. In addition, increased initiatives by several health protection agencies to recommend the vaccination of teens and preteens have boosted the demand for these vaccines in numerous countries.  


Meanwhile, the Asia Pacific market is anticipated to expand at a significant pace. The impressive growth of the Asia Pacific market for meningitis vaccines is primarily driven by rapid rise in populations prone to the disease incidence and the growing awareness of prevention methods.  


Connect With Us

Market Research Industries

Why Profshare?

  High Data Accuracy

Precise research methodology, numerous analysis models & up to date data resources to achive most accurate market values.

 Customization as Needed

We can tailored the report as per your requirments & budget, Most of our clients prefer custom reports.

  Budget Friendly Solution

We have quality market data for all types of budget & so now get best out of your market research budget.

  Quality Support

Be assured of receving satisfactory analyst support to understand research report in-detail.